Post-earnings recap
Reported
Fri, Aug 7, 2026
EPS actual
$-3.49
EPS est.
$-4.10
EPS surprise
+14.88%
1-day move
+21.42%
Claritev Corporation reported a significant earnings miss on EPS, which typically raises concerns among investors. However, the stock reacted positively, rising by 21.42%. This increase may reflect investor optimism about potential future recovery or other underlying factors not captured in the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.49 | $1.58 | +14.88% |
| Revenue | — | $250M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Claritev Corporation operates in the Health Care Technology sector, focusing on innovative solutions that improve patient care and streamline healthcare processes. With a market cap of $1 billion, the company plays a crucial role in the growing intersection of technology and healthcare, which is increasingly important as the industry evolves.
Last quarter
In Q1-2026, Claritev reported an EPS of -$4.41, missing estimates by 15.75%. The stock reacted negatively, dropping 8.54% the following day.
Management promises and guidance
EPS beat streak
1Q
EPS beat rate
17%
Avg EPS surprise
-40.62%
Avg 1-day reaction
+9.26%
Analysts are cautiously optimistic about Claritev's upcoming earnings, with expectations for a modest recovery in EPS and revenue. However, the company has a history of missing estimates, which adds uncertainty.
Bull case
If Claritev meets or exceeds EPS and revenue expectations, it could signal a turnaround and boost investor confidence, leading to a significant stock price increase.
Bear case
Conversely, if the company fails to meet expectations again, it could further erode investor trust and lead to a sharp decline in stock price.
Key metrics to watch
EPS
$1.58Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$250MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will EPS meet the consensus estimate of $1.58?
This number is critical as it reflects the company's ability to recover from previous losses and regain investor confidence.
Q2
What specific revenue figures can management provide to support the $250M consensus?
Revenue performance is essential for understanding market demand and the company's growth trajectory.
—
Est. EPS
$1.44
Est. Rev
$23.1B
Impl. Move
±10.9%
Why consensus could be wrong
The Street may be underestimating the potential for a turnaround, as Claritev's recent operational changes could lead to better-than-expected results this quarter.
Supporting evidence
The company has committed to improving operational efficiency, which could positively impact margins.
The options market is pricing a high move, indicating that traders expect significant news that could surprise the market.
Key risk
If management provides strong guidance or reveals new contracts, it could invalidate the current consensus.
Pre-commit to what would confirm each case.
The market is closely watching these figures to gauge whether Claritev can overcome its recent performance issues.
Bull confirmed if
Achieving an EPS of $1.58 or better would confirm a positive turnaround narrative.
Bear confirmed if
An EPS significantly below $1.58 would reinforce concerns about the company's profitability.
What the market is pricing for the move.
Implied Move
±57.32%
Historical Avg
±12.2%
The options market is pricing in a significant potential movement in the stock, indicating high uncertainty around the earnings report.
Options are pricing ±57.3% while CTEV has averaged ±12.2% over the last 6 prints — setup is pricing rich.
ATM IV
1.2%
30d HV
210.8%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
82.89%
of float
Insider
7.26%
of float
Holders
151
institutions
Top Holders· as of Jun 2026
H&F Corporate Investors VIII, Ltd.
3,887,858 sh · $97.3M
22.94%
Flat
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Claritev beats expectations, history suggests the stock could rise by around 6.82%, confirming a positive outlook.
In line / cautious
If results are in line but management's commentary is cautious, the stock may remain stable or see minor fluctuations.
Miss
A miss could lead to a decline of around 6.82%, reflecting continued investor skepticism.
The lines on the call that would change the story.
Ares Management LLC
1,863,105 sh · $46.6M
10.99%
Flat
Arini Capital Management Ltd
1,534,687 sh · $38.4M
9.06%
Flat
Public Investment Fund
1,281,250 sh · $32.1M
7.56%
Flat
Beach Point Capital Management LP
770,612 sh · $19.3M
4.55%
-3.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.